| TAH Drug Code | ERELV |
|---|---|
| Indications | Asthma, and chronic obstructive pulmonary disease of maintenance. |
| Dosing | One inhalation of Relvar Ellipta 92/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to 184/22 micrograms, which may provide additional improvement in asthma control. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to fluticasone, vilanterol, or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required. |
| Adverse Effects | Common Gastrointestinal: Difficulty talking (2% ), Oropharyngeal candidiasis, Pain, Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater ), Cough (1% or greater ), Nasopharyngitis (9% to 10% ), Sinusitis (2% or greater ), Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia, Disorder of cardiovascular system, Electrocardiogram abnormal, Premature beats (2% or greater ), Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density, Fracture of bone (2% ) Respiratory: Death, Asthma-related, Paradoxical bronchospasm, Pneumonia (2% or greater ) Other: Angioedema |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ERELV2 |
|---|---|
| Indications | For asthma in aged 18 years and over. |
| Dosing | One inhalation of Relvar Ellipta 184/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to 184/22 micrograms, which may provide additional improvement in asthma control. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to fluticasone, vilanterol, or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required. |
| Adverse Effects | Common Gastrointestinal: Difficulty talking (2% ), Oropharyngeal candidiasis, Pain, Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater ), Cough (1% or greater ), Nasopharyngitis (9% to 10% ), Sinusitis (2% or greater ), Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia, Disorder of cardiovascular system, Electrocardiogram abnormal, Premature beats (2% or greater ), Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density, Fracture of bone (2% ) Respiratory: Death, Asthma-related, Paradoxical bronchospasm, Pneumonia (2% or greater ) Other: Angioedema |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |